{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:53:53Z","timestamp":1790056433539,"version":"4.0.1"},"reference-count":94,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.bbmt.2020.04.003","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T10:57:24Z","timestamp":1586948244000},"page":"e183-e191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Exploring the Dilemma of Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy: To Transplant or Not?"],"prefix":"10.1016","volume":"26","author":[{"given":"Stella","family":"Bouziana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Bouzianas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2020.04.003_bib0001","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: progress through collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0002","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0003","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(12)70580-6","article-title":"Relapsed childhood acute lymphoblastic leukaemia","volume":"14","author":"Bhojwani","year":"2013","journal-title":"Lancet Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.bbmt.2020.04.003_bib0004","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdw025","article-title":"Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Hoelzer","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0005","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the international CORAL study","volume":"51","author":"Van Den Neste","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0006","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"Suppl 5","key":"10.1016\/j.bbmt.2020.04.003_bib0007","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0008","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","article-title":"Immune escape mechanisms as a guide for cancer immunotherapy","volume":"21","author":"Beatty","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0009","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0010","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00262-014-1568-1","article-title":"Engineered T cells for cancer therapy","volume":"63","author":"June","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0011","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0012","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0013","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.bbmt.2018.12.068","article-title":"Clinical utilization of chimeric antigen receptor T cells in B cell acute lymphoblastic leukemia: an expert opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation","volume":"25","author":"Kansagra","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0014","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-018-0164-6","article-title":"The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL","volume":"9","author":"Hucks","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0015","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0016","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0017","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0018","doi-asserted-by":"crossref","first-page":"E472","DOI":"10.3390\/cells8050472","article-title":"Limitations in the design of chimeric antigen receptors for cancer therapy","volume":"8","author":"Stoiber","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0019","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0020","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0021","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0022","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0023","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/bloodadvances.2019000151","article-title":"Tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion","volume":"3","author":"Bishop","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0024","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0025","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.7505","article-title":"Updated safety and long-term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R\/R aggressive NHL","volume":"36","author":"Abramson","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0026","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0027","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"25","author":"Jain","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0028","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood.V128.22.221.221","article-title":"Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed\/refractory acute lymphoblastic leukemia (ALL)","volume":"128","author":"Grupp","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0029","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.3048","article-title":"Prolonged functional persistence of CD19 CAR-T cell products of defined CD4:CD8 composition and transgene expression determines durability of MRD\u2010negative ALL remission","volume":"34","author":"Gardner","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0030","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.3024","article-title":"Updated results from ZUMA\u20103, a phase 1\/2 study of KTE\u2010C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high\u2010burden relapsed\/refractory acute lymphoblastic leukemia (R\/R ALL)","volume":"35","author":"Shah","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0031","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.102","article-title":"Rate of durable complete response in ALL, NHL, and CLL after immunotherapy with optimized lymphodepletion and defined composition CD19 CAR\u2010T cells","volume":"34","author":"Turtle","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0032","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1189\/jlb.5RU0817-315R","article-title":"Acute lymphoblastic leukemia relapse after CD19-targeted chimeric antigen receptor T cell therapy","volume":"102","author":"Wang","year":"2017","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0033","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/bmt.2016.20","article-title":"Hematopoietic stem cell transplantation in Europe 2014: more than 40,000 transplants annually","volume":"51","author":"Passweg","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0034","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/S2352-3026(19)30158-9","article-title":"Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis","volume":"6","author":"Shouval","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0035","article-title":"Comparison of outcomes in hematological malignancies treated with haploidentical or HLA-identical sibling hematopoietic stem cell transplantation following myeloablative conditioning: a meta-analysis","volume":"13","author":"Chen","year":"2018","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"10.1016\/j.bbmt.2020.04.003_bib0036","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2018-99-112599","article-title":"Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory (r\/r) acute lymphoblastic leukemia","volume":"132","author":"Grupp","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0037","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.7008","article-title":"Durable long\u2010term survival of adult patients with relapsed B\u2010ALL after CD19 CAR (19\u201028z) T\u2010cell therapy","volume":"35","author":"Park","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0038","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19\u2010targeted T cells in patients with relapsed or chemotherapy refractory B\u2010cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0039","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1038\/s41375-019-0615-5","article-title":"CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives","volume":"33","author":"Mohty","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0040","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1182\/blood.V128.22.2801.2801","article-title":"Efficacy and safety of CTL019 in the first US phase II multicenter trial in pediatric relapsed\/refractory acute lymphoblastic leukemia: results of an interim analysis","volume":"128","author":"Maude","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0041","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.bbmt.2020.04.003_bib0042","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1182\/blood-2018-99-115599","article-title":"Long term follow-up after SCRI-CAR19v1 reveals late recurrences as well as a survival advantage to consolidation with HCT after CAR T cell induced remission","volume":"132","author":"Summers","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0043","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0044","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1182\/blood.V126.23.684.684","article-title":"Safety and response of incorporating CD19 chimeric antigen receptor T cell therapy in typical salvage regimens for children and young adults with acute lymphoblastic leukemia","volume":"126","author":"Lee","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0045","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/blood.V128.22.218.218","article-title":"Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine\/cyclophosphamide preparative regimen and post-CAR hematopoietic stem cell transplantation","volume":"128","author":"Lee","year":"2016","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.bbmt.2020.04.003_bib0046","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.bbmt.2017.12.018","article-title":"Chimeric antigen receptor T-cell (CAR-T) therapy can render patients with ALL into PCR-negative remission and can be an effective bridge to transplant (HCT)","volume":"24","author":"Shalabi","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0047","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0048","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0049","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0050","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0051","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/asheducation-2018.1.16","article-title":"Are CAR T cells better than antibody or HCT therapy in B-ALL?","volume":"2018","author":"Pulsipher","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0052","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood.2019003821","article-title":"Beat pediatric ALL MRD: CD28 CAR T and transplant","volume":"134","author":"Ruella","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0053","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/bloodadvances.2019000593","article-title":"Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy","volume":"3","author":"Shadman","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0054","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","article-title":"Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy","volume":"16","author":"Mahadeo","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0055","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s11899-018-0470-x","article-title":"CAR-T cell therapy for acute lymphoblastic leukemia: transforming the treatment of relapsed and refractory disease","volume":"13","author":"Pehlivan","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0056","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1182\/blood.V126.23.682.682","article-title":"Implications of minimal residual disease negative complete remission (MRD-CR) and allogeneic stem cell transplant on safety and clinical outcome of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed, refractory B-cell ALL","volume":"126","author":"Park","year":"2015","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.bbmt.2020.04.003_bib0057","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/blood-2019-121836","article-title":"Association of genetic factors with long-term outcome in refractory r\/r B-ALL patients after CAR T-cell therapy","volume":"134","author":"Pan","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0058","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J Clin Invest"},{"issue":"Suppl 1","key":"10.1016\/j.bbmt.2020.04.003_bib0059","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/blood-2019-125503","article-title":"Analysis of factors predicting treatment response of 254 patients who received CD19-targeted CAR-T cell therapy for relapsed\/refractory (R\/R) B-cell acute lymphoblastic leukemia (B-ALL)","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0060","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0061","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood-2017-05-782888","article-title":"Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy","volume":"130","author":"Nagel","year":"2017","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.bbmt.2020.04.003_bib0062","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2019-132057","article-title":"Detectable circulating tumor DNA 28 days after the CD19 CAR-T cell therapy, axicabtagene ciloleucel, is associated with poor outcomes in patients with diffuse large B-cell lymphoma","volume":"134","author":"Frank","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0063","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ncponc0666","article-title":"Increased intensity lymphodepletion and adoptive immunotherapy\u2013how far can we go","volume":"3","author":"Muranski","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0064","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0065","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl 1","key":"10.1016\/j.bbmt.2020.04.003_bib0066","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-cell therapy","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0067","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jcyt.2017.06.001","article-title":"Building blocks for institutional preparation of CTL019 delivery","volume":"19","author":"McGuirk","year":"2017","journal-title":"Cytotherapy"},{"issue":"Suppl 1","key":"10.1016\/j.bbmt.2020.04.003_bib0068","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2018-99-114152","article-title":"Axicabtagene ciloleucel (axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory large B-cell lymphoma: real world experience","volume":"132","author":"Nastoupil","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.bbmt.2020.04.003_bib0069","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/blood-2018-99-120013","article-title":"Safety of axicabtagene ciloleucel CD19 CAR T-cell therapy in elderly patients with relapsed or refractory large B-cell lymphoma","volume":"132","author":"Sano","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.bbmt.2020.04.003_bib0070","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1182\/blood-2019-124364","article-title":"Medicare patients receiving chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma: a first real-world look at patient characteristics, healthcare utilization and costs","volume":"134","author":"Kilgore","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.bbmt.2020.04.003_bib0071","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1182\/blood-2019-121715","article-title":"Patient experience of chimeric antigen receptor (CAR)-T cell therapy vs. stem cell transplant: longitudinal patient reported adverse events, cognition and quality of life","volume":"134","author":"Sidana","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0072","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.bbmt.2013.05.021","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita","volume":"19","author":"Gadalla","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0073","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/leu.2016.164","article-title":"The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome","volume":"30","author":"Lee","year":"2016","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1016\/j.bbmt.2020.04.003_bib0074","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood-2019-130983","article-title":"Tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy for adults with diffuse large B-cell lymphoma (DLBCL): real world experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) cellular therapy (CT) registry","volume":"134","author":"Jaglowski","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.bbmt.2020.04.003_bib0075","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1182\/blood-2019-127490","article-title":"A multicenter retrospective analysis of clinical outcomes, toxicities, and patterns of use in institutions utilizing commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B-cell lymphomas","volume":"134","author":"Riedell","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0076","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.bbmt.2013.01.024","article-title":"Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma","volume":"19","author":"Hamadani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0077","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","article-title":"Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry","volume":"29","author":"van Kampen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0078","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bjh.14046","article-title":"Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation","volume":"174","author":"Fenske","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0079","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/bloodadvances.2018027748","article-title":"PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL","volume":"3","author":"Dreger","year":"2019","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"10.1016\/j.bbmt.2020.04.003_bib0080","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1182\/blood-2018-99-110747","article-title":"Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy","volume":"132","author":"Chow","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0081","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1016\/j.bbmt.2019.06.036","article-title":"Understanding and managing large B cell lymphoma relapses after chimeric antigen receptor T cell therapy","volume":"25","author":"Byrne","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl 1","key":"10.1016\/j.bbmt.2020.04.003_bib0082","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1182\/blood-2019-129015","article-title":"Circulating DNA for molecular response prediction, characterization of resistance mechanisms and quantification of CAR T-cells during axicabtagene ciloleucel therapy","volume":"134","author":"Sworder","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.bbmt.2020.04.003_bib0083","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/blood-2018-99-117199","article-title":"Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity","volume":"132","author":"Jacobson","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0084","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/blood.V126.23.183.183","article-title":"Sustained remissions following chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas","volume":"126","author":"Schuster","year":"2015","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.bbmt.2020.04.003_bib0085","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1182\/blood-2019-128068","article-title":"Upregulation of senescent\/exhausted phenotype of CAR T cells and induction of both Treg and myeloid suppressive cells correlate with reduced response to CAR T cell therapy in relapsed\/refractory B cell malignancies","volume":"134","author":"Beider","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.bbmt.2020.04.003_bib0086","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1182\/blood-2019-130815","article-title":"Identification of Two CAR T-cell populations associated with complete response or progressive disease in adult lymphoma patients treated with axi-cel","volume":"134","author":"Good","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0087","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.7562","article-title":"Association of high baseline metabolic tumor volume with response following axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"37","author":"Dean","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0088","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.bbmt.2017.11.023","article-title":"Outcomes after allogeneic stem cell transplantation in patients with double-hit and double-expressor lymphoma","volume":"24","author":"Herrera","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0089","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.hoc.2019.03.005","article-title":"Allogeneic stem cell transplantation and chimeric antigen receptor (CAR) T-cell therapy for the treatment of non-Hodgkin lymphoma","volume":"33","author":"Hunter","year":"2019","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0090","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1002\/ajh.25416","article-title":"CARs of the future","volume":"94","author":"Daniyan","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0091","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1097\/HS9.0000000000000172","article-title":"CAR T cells: a snapshot on the growing options to design a CAR","volume":"3","author":"Holzinger","year":"2019","journal-title":"Hemasphere"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0092","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bbmt.2020.04.003_bib0093","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by Anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.bbmt.2020.04.003_bib0094","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2019-127508","article-title":"Pivotal safety and efficacy results from Transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed\/refractory (R\/R) large B cell lymphomas","volume":"134","author":"Abramson","year":"2019","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120302111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120302111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:11:35Z","timestamp":1761059495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879120302111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":94,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1083879120302111"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.04.003","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the Dilemma of Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy: To Transplant or Not?","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}